Early prediction of the impact of public health policies on obesity and lifetime risk of type 2 diabetes: A modelling approach.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 12 06 2023
accepted: 17 03 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 28 3 2024
Statut: epublish

Résumé

Help public health decision-making requires a better understanding of the dynamics of obesity and type 2 diabetes and an assessement of different strategies to decrease their burdens. Based on 97,848 individual data, collected in the French Health, Health Care and Insurance Survey over 1998-2014, a Markov model was developed to describe the progression of being overweight to obesity, and the onset of type 2 diabetes. This model traces and predicts 2022-2027 burdens of obesity and type 2 diabetes, and lifetime risk of diabetes, according to different scenarios aiming at minimum to stabilize obesity at 5 years. Estimated risks of type 2 diabetes increase from 0.09% (normal weight) to 1.56% (obesity II-III). Compared to the before 1995 period, progression risks are estimated to have nearly doubled for obesity and tripled for type 2 diabetes. Consequently, over 2022-2027, the prevalence of obesity and type 2 diabetes will continue to increase from 17.3% to 18.2% and from 7.3% to 8.1%, respectively. Scenarios statibilizing obesity would require a 22%-decrease in the probability of move up (scenario 1) or a 33%-increase in the probability of move down (scenario 2) one BMI class. However, this stabilization will not affect the increase of diabetes prevalence whereas lifetime risk of diabetes would decrease (30.9% to 27.0%). Combining both scenarios would decrease obesity by 9.9%. Only the prevalence of obesity III shows early change able to predict the outcome of a strategy: for example, 6.7%-decrease at one year, 13.3%-decrease at two years with scenario 1 stabilizing obesity at 5 years. Prevalences of obesity and type 2 diabetes will still increase over the next 5 years. Stabilizing obesity may decrease lifetime risks of type 2 diabetes without affecting its short-term prevalence. Our study highlights that, to early assess the effectiveness of their program, public health policy makers should rely on the change in prevalence of obesity III.

Identifiants

pubmed: 38547299
doi: 10.1371/journal.pone.0301463
pii: PONE-D-23-16918
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0301463

Informations de copyright

Copyright: © 2024 Bauvin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have no competing interests to declare that are relevant to the content of this article.

Auteurs

Pierre Bauvin (P)

Inserm, CHU Lille, U1286 -INFINITE-Institute for Translational Research in Inflammation, Université de Lille, Lille, France.

Claire Delacôte (C)

Inserm, CHU Lille, U1286 -INFINITE-Institute for Translational Research in Inflammation, Université de Lille, Lille, France.

Line Carolle Ntandja Wandji (LCN)

Services Maladies de l'Appareil Digestif, Hôpital Claude Huriez, CHRU Lille, Lille, France.

Guillaume Lassailly (G)

Inserm, CHU Lille, U1286 -INFINITE-Institute for Translational Research in Inflammation, Université de Lille, Lille, France.
Services Maladies de l'Appareil Digestif, Hôpital Claude Huriez, CHRU Lille, Lille, France.

Violeta Raverdy (V)

Inserm, CHU Lille, U1190-EGID, Univ. Lille, Lille, France.

François Pattou (F)

Inserm, CHU Lille, U1190-EGID, Univ. Lille, Lille, France.

Sylvie Deuffic-Burban (S)

Inserm, CHU Lille, U1286 -INFINITE-Institute for Translational Research in Inflammation, Université de Lille, Lille, France.
Inserm IAME, Université Paris Cité and Université Sorbonne Paris Nord, Paris, France.

Philippe Mathurin (P)

Inserm, CHU Lille, U1286 -INFINITE-Institute for Translational Research in Inflammation, Université de Lille, Lille, France.
Services Maladies de l'Appareil Digestif, Hôpital Claude Huriez, CHRU Lille, Lille, France.

Classifications MeSH